Evaluation of the AdvanSure One-Stop COVID-19 Plus Kit for SARS-CoV-2 Detection Using a Streamlined RNA Extraction Method
Annals of Laboratory Medicine · 2023
DOI: 10.3343/alm.2023.43.5.508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Laboratory Medicine, 2023. Verfasst von Tae Yeul Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Foundation of Korea, Ministry of Science and ICT, LG Chem.
Abstract (Originalsprache)
Real-time reverse transcription (rRT)-PCR, which is the reference standard for the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, generally involves a time-consuming and costly RNA extraction step prior to amplification. We evaluated the performance of the AdvanSure One-Stop COVID-19 Plus Kit (LG Chem, Seoul, Korea), a novel rRT-PCR assay that can detect SARS-CoV-2 within 90 minutes using a streamlined RNA extraction method. In total, 509 nasopharyngeal swab (NPS) specimens (SARS-CoV-2 positive: N=205; SARS-CoV-2 negative: N=304) previously tested using the PowerChek SARS-CoV-2 Real-time PCR Kit (Kogene Biotech, Seoul, Korea) were tested using the AdvanSure assay. The limit of detection (LOD) of the AdvanSure assay was determined using serially diluted inactivated SARS-CoV-2. The positive and negative percent agreements between the AdvanSure and PowerChek assays were 99.5% (204/205) and 99.3% (302/304), respectively. The LODs of the AdvanSure assay for SARS-CoV-2 nucleocapsid and spike/RNA-dependent RNA polymerase genes were 672 and 846 copies/mL, respectively. The results show that the performance of the AdvanSure assay is comparable to that of the PowerChek assay used for routine SARS-CoV-2 testing, suggesting that the AdvanSure assay is a useful diagnostic tool for rapid and accurate detection of SARS-CoV-2 infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Center for Clinical Medicine, Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea.
- Biomedical Engineering Research Center, Smart Healthcare Research Institute, Samsung Medical Center, Seoul, Korea.
- Department of Medical Device Management and Research, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Korea.
ORCID-Profile: Tae Yeul Kim, Hyang Jin Shim, Eunjung Jeong, Minhee Kang, Ja-Hyun Jang, Hee Jae Huh, Nam Yong Lee
Förderung
- National Foundation of Korea
- Ministry of Science and ICT
- LG Chem
Zitieren
APA
Kim, T. Y., Shim, H. J., Jeong, E., Kang, M., Jang, J. H., Huh, H. J., & Lee, N. Y. (2023). Evaluation of the AdvanSure One-Stop COVID-19 Plus Kit for SARS-CoV-2 Detection Using a Streamlined RNA Extraction Method. Annals of Laboratory Medicine. https://doi.org/10.3343/alm.2023.43.5.508
Vancouver
Kim TY, Shim HJ, Jeong E, Kang M, Jang JH, Huh HJ, et al. Evaluation of the AdvanSure One-Stop COVID-19 Plus Kit for SARS-CoV-2 Detection Using a Streamlined RNA Extraction Method. Annals of Laboratory Medicine. 2023. doi:10.3343/alm.2023.43.5.508
BibTeX
@article{Kim2023,
author = {Kim, Tae Yeul and Shim, Hyang Jin and Jeong, Eunjung and Kang, Minhee and Jang, Ja-Hyun and Huh, Hee Jae and Lee, Nam Yong},
title = {Evaluation of the AdvanSure One-Stop COVID-19 Plus Kit for SARS-CoV-2 Detection Using a Streamlined RNA Extraction Method},
journal = {Annals of Laboratory Medicine},
year = {2023},
doi = {10.3343/alm.2023.43.5.508}
}
EUVIMED